Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
Conditions
Interventions
KFA115
pembrolizumab
Locations
19
United States
Massachusetts General Hospital .
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
NYU School of Medicine
New York, New York, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
Novartis Investigative Site
Toronto, Ontario, Canada
Start Date
October 26, 2022
Primary Completion Date
September 1, 2027
Completion Date
September 1, 2027
Last Updated
January 6, 2026
NCT06855771
NCT06758401
NCT06120140
NCT04895709
NCT05039801
NCT06391099
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions